Home→Healthcare Professionals→NICE Quality Standards→Managing Drug Allergy: NICE Guideline (CG183)

NICE Guideline (CG183)

The NICE guideline CG183 provides comprehensive recommendations for the diagnosis, documentation, and management of drug allergies in adults, children, and young people. It emphasises the importance of thorough patient histories, appropriate allergy testing, and clear documentation to prevent future adverse reactions. The guideline also highlights the need for effective patient education, ensuring that individuals are well-informed about their drug allergies and how to avoid triggers. This guidance aims to improve patient safety and healthcare outcomes.

Free Monthly Newsletter

Subscribe to our free monthly newsletter for healthcare professionals

Key Priorities for Implementing Drug Allergy Management

The NICE guideline CG183 outlines critical priorities for effectively managing drug allergies. These include taking comprehensive drug allergy histories for all patients, ensuring proper documentation of allergies in medical records, and educating patients and healthcare providers on recognising and avoiding allergens. The guideline also stresses the importance of providing patients with detailed information about their allergies, including how to manage future risks and what to do in an emergency situation.

Recommendations from NICE Guideline on Drug Allergy

The NICE guideline CG183 offers comprehensive recommendations for the safe management of drug allergies. It underscores the importance of obtaining a detailed drug allergy history from all patients, which includes identifying any previous allergic reactions and the specific drugs involved. This history should be meticulously documented in the patient’s medical records to ensure that all healthcare providers are fully informed.

Documentation and Communication

Clear and accurate documentation of drug allergies is vital. The guideline recommends that all identified drug allergies be prominently noted in both the patient’s electronic and paper medical records. This information should be updated regularly and communicated across all healthcare settings, including during hospital admissions, outpatient visits, and community care. The guideline also advises the use of patient-held records, where individuals carry a summary of their drug allergies, ensuring that any healthcare provider can access this critical information quickly.

Patient Education and Support

Education is a key aspect of managing drug allergies. The guideline recommends that patients be provided with detailed, easy-to-understand information about their drug allergies. This includes information on how to avoid triggering substances, what symptoms to look out for, and what steps to take in case of accidental exposure. Patients should also be educated on the importance of informing all healthcare providers, including pharmacists, about their drug allergies.

Specialist Referral and Testing

For complex cases, the guideline recommends referral to specialist allergy services for further evaluation and testing. This is particularly important in cases where the allergy history is unclear, or the patient has experienced severe reactions. Specialist assessment may include skin tests, blood tests, or drug challenge tests to accurately identify the specific drug allergens and confirm the diagnosis.

Emergency Action Plans

The guideline also highlights the importance of emergency action plans for patients with a history of severe drug allergies. These plans should outline the immediate steps to be taken if a reaction occurs, including the use of adrenaline auto-injectors, if appropriate, and when to seek emergency medical help. Patients should be familiar with their action plans and have the necessary medications readily available.

Context of NICE Guideline on Drug Allergy

Drug allergies pose significant challenges in healthcare due to the complexity of diagnosing and managing these conditions. The NICE guideline CG183 was developed to address these challenges by providing evidence-based recommendations for the identification, documentation, and management of drug allergies. The guideline aims to improve patient safety by ensuring that drug allergies are accurately recorded, communicated across healthcare settings, and that patients receive appropriate education and support to manage their condition effectively.

NICE Guideline (CG183)

This content is based on the principles outlined in the Managing Drug Allergy: NICE Guideline (CG183), tailored to the needs of healthcare professionals in the UK.

NICE Guideline on Drug Allergy

More from NICE

NICE Quality Standard for Food Allergy

The NICE quality standard for food allergy (QS118) outlines essential practices for the diagnosis and management of food allergies, particularly in children and young people.

Read more

NICE Guideline on Anaphylaxis

The NICE guideline CG134 outlines crucial recommendations for the recognition, emergency treatment, and ongoing management of anaphylaxis.

Read more

NICE Quality Standard for Anaphylaxis

The NICE quality standard for anaphylaxis (QS119) provides essential guidance to improve the care and management of individuals at risk of or experiencing anaphylaxis.

Read more

NICE Guideline on Food Allergy in Children and Young People

The NICE guideline CG116 addresses the growing concern of food allergies in children and young people. It emphasises the need for early identification through a detailed allergy-focused clinical history and the use of appropriate diagnostic tests.

Read more